RANKL Inhibition in Breast Cancer Neoadjuvant Therapy
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
GeparX Phase IIb Trial
- May 19, 2022
GeparX Phase IIb trial evaluated denosumab (RANKL inhibitor) combined with neoadjuvant chemotherapy in primary breast cancer patients. Results published in JAMA Oncology by Jens-Uwe Blohmer et al., Charité University.
Key Findings
Denosumab combined with standard neoadjuvant chemotherapy demonstrates enhanced pathological response rates compared to chemotherapy alone, suggesting potential benefit of RANKL pathway inhibition in improving chemotherapy efficacy in breast cancer.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.